Fig. 2
From: CCN3 is dynamically regulated by treatment and disease state in multiple sclerosis
Obesity-induced changes in plasma CCN3 levels are evident in MS. Plasma CCN3 levels in lean vs. obese cohorts (a), CCN3 levels (b) and leptin levels (c) in plasma from obese patients before and after 12 weeks of GLP-1 agonist therapy. Corresponding plasma CCN3 levels and BMI in healthy controls and MS (d) and stratified by disease phase and treatment (e). Abbreviations: HC, healthy control; MS, multiple sclerosis; RRMS, relapsing-remitting MS; TN, treatment-naïve; Nat, natalizumab treatment; IFN, interferon-β treatment; MS-Pr, progressive MS